Sumitomo subscribes to Gene Logic's GeneExpress Database

Under the terms of the agreement, Sumitomo will subscribe to the BioExpress and ToxExpress modules of the GeneExpress Suite.



Under the terms of the agreement, Sumitomo will subscribe to the BioExpress and ToxExpress modules of the GeneExpress Suite. BioExpress provides gene expression and associated information from a broad range of normal and diseased human tissues, tissues from model animal systems and human and animal cell lines for use in target identification and target validation studies.

ToxExpress is a reference library of toxicity markers derived from examination of known toxic compounds in animal model systems and across human and rat primary cell lines. The module is used for prioritizing candidate compounds currently under development.

In addition, Gene Logic will construct a separate customized database containing segments of Sumitomo's proprietary data, which will then be integrated into the non-proprietary data and accessed through the GeneExpress Suite. This integration will allow Sumitomo researchers to view a combination of proprietary and non-proprietary data.

As Gene Logic and Sumitomo use the common GeneChip technology, we can integrate our data with the data from the GeneExpress and utilize them together across our entire research team, said Kikuo Ishizumi, Director, GM, Research Division for Sumitomo Pharmaceuticals. The agreement with Gene Logic is a significant part of our continuing efforts to furnish our genomics-based research infrastructure, and we believe that the subscription to the GeneExpress Suite enables us to greatly accelerate our drug discovery process.

This broad subscription agreement establishes a firm base of critical gene statement data and analysis capabilities to support Sumitomo's global research programs, said David Murray, Senior Vice President, Marketing and Sales for Gene Logic. The integration of our data with their data will serve to expand the overall value of Sumitomo's ongoing research initiatives and is consistent with our ongoing strategy of providing gene statement-based solutions that deliver valuable insights into the mechanisms of disease for improved management of drug development pipelines.


Since you're here...
... and value our content, you should sign-up to our newsletter. Sign up here

comments powered by Disqus